Skip to content
Inciteful Med

Standard of Care and Treatment for MPS IV

Last updated:

The standard of care for Morquio Syndrome (MPS IV) requires a multidisciplinary approach. Primary treatments include Enzyme Replacement Therapy (ERT) to improve endurance and respiratory function, along with specialized surgeries to manage skeletal deformities and protect the airway.

Key Takeaways

  • • Enzyme Replacement Therapy (ERT) with elosulfase alfa is the standard medical treatment for MPS IVA, helping to improve physical endurance and respiratory function.
  • • Because ERT cannot easily reach cartilage and bone, orthopedic and spinal surgeries remain a necessary part of managing skeletal complications.
  • • Anesthesia requires specialized planning and extreme caution due to severe airway narrowing and neck instability risks.
  • • Supportive therapies, including CPAP for sleep apnea and dedicated chronic pain management, are crucial for maintaining daily quality of life.

Managing Morquio Syndrome (MPS IV) requires a lifelong, multidisciplinary care approach [1]. Because the condition affects so many parts of the body—from the bones to the heart and lungs—treatment is focused on improving quality of life, increasing physical endurance, and preventing serious complications [1][2].

Enzyme Replacement Therapy (ERT)

For individuals with MPS IVA (Type A), the standard medical treatment is Enzyme Replacement Therapy (ERT) using a medication called elosulfase alfa (Vimizim) [3].

  • How it works: The medicine is given through a weekly intravenous (IV) infusion [4]. It provides a working version of the missing GALNS enzyme to help the body break down the buildup of sugars in the blood and soft tissues [3][1].
  • Logistics: These infusions are a significant time commitment, typically taking several hours once a week [3]. Many patients have a “port” surgically placed to make IV access easier. Infusions are often done at a specialized infusion center, though home infusions may be possible for some stable patients.
  • The Benefits: Clinical trials and real-world studies show that ERT consistently improves endurance [5]. Patients often notice they can walk further—measured by the 6-minute walk test (6MWT)—and climb stairs more easily [6][7]. It also helps stabilize or improve respiratory function [8][5].
  • The Limitations: It is important to understand that ERT has a limited impact on bones and cartilage [9]. Because cartilage is avascular (meaning it does not have a direct blood supply), the enzyme cannot easily reach the areas where the most severe skeletal damage occurs [9][10]. This means that even with ERT, skeletal changes will likely continue, and surgeries will still be necessary [9][11].
  • Safety Warning: Vimizim carries a Black Box Warning for the risk of severe allergic reactions, including anaphylaxis, during or shortly after infusions [3]. Because of this risk, infusions are closely monitored by healthcare professionals, and patients are usually pre-medicated with antihistamines to prevent reactions [3].

Common Surgical Interventions

Surgery is a frequent and necessary part of the Morquio journey to correct physical deformities and protect vital organs [1][12].

  • Spinal Surgery: The most critical surgeries are often in the neck (cervical spine). Procedures like cervical decompression or fusion are used to stabilize the neck and prevent the spinal cord from being pinched [1][13].
  • Orthopedic Surgery: To help with mobility, patients may need guided growth (using small plates) to correct “knock-knees” (genu valgum) [14][15]. Hip surgeries, such as pelvic osteotomies, may also be needed to fix hip dysplasia and improve joint mechanics [16][15].
  • ENT and Airway Surgery: Procedures like ear tubes (myringotomy) to manage chronic ear infections and hearing loss are common [17]. Surgery to remove the tonsils and adenoids is also frequently used to help open up the airway [17].

Chronic Pain Management

Because of severe skeletal dysplasias, joint instability, and repeated surgeries, chronic pain is a daily reality for many individuals with Morquio Syndrome [1]. Effective management requires a dedicated approach, often involving a pain management specialist. Treatment may include safe medications tailored to the individual (avoiding those that could depress breathing if sleep apnea is present) and low-impact physical therapies designed to support joint health without causing further damage [1][11].

Supportive Therapies

Beyond medicine and surgery, “supportive care” helps manage daily symptoms and long-term health:

  • Respiratory Support: Because airway narrowing is common, many patients use CPAP or BiPAP machines at night to help them breathe while they sleep and manage obstructive sleep apnea [18][19].
  • Hearing and Vision Care: Regular audiology and ophthalmology check-ups are standard to monitor for hearing loss and corneal clouding, ensuring access to necessary tools like hearing aids [1][20].
  • Anesthesia Precautions: Any surgery for a person with Morquio Syndrome requires a specialized anesthesia plan [21]. Because of the risks to the airway and neck stability, it is mandatory to work with an anesthesiologist experienced in rare skeletal disorders [21][22].

Frequently Asked Questions

How does Enzyme Replacement Therapy (ERT) work for Morquio Syndrome?
ERT involves a weekly intravenous infusion that provides a working version of the enzyme your body is missing. This helps clear the buildup of complex sugars in the blood and soft tissues, which can improve physical endurance and breathing.
Will ERT cure the bone and joint problems caused by MPS IV?
While ERT improves stamina and breathing, it has limited effect on bones and cartilage because these tissues lack a direct blood supply. As a result, skeletal changes usually continue, and orthopedic surgeries are still necessary.
What are the most common surgeries needed for someone with MPS IV?
Patients frequently need cervical spine surgery to protect the spinal cord, orthopedic procedures to correct knock-knees or hip dysplasia, and ear, nose, and throat surgeries to manage chronic infections and maintain an open airway.
Why is anesthesia a special concern for individuals with Morquio Syndrome?
Because of narrowed airways and extreme instability in the neck and spine, general anesthesia carries very high risks. It is mandatory for patients to work with a specialized anesthesiologist experienced in rare skeletal disorders during any procedure.
How is sleep apnea managed in patients with MPS IV?
Because airway narrowing and obstructive sleep apnea are common complications, many patients use CPAP or BiPAP machines at night. These devices provide steady air pressure to help keep the airway open while sleeping.

Questions for Your Doctor

  • • How will Enzyme Replacement Therapy (ERT) be monitored to see if it is improving endurance and breathing?
  • • Since ERT does not reach the bones and cartilage well, what is our long-term plan for managing skeletal changes?
  • • What is the protocol for pre-medicating prior to a Vimizim infusion to prevent allergic reactions?
  • • How often is a sleep study required to check for airway obstruction or sleep apnea?
  • • When is the best 'surgical window' for correcting knock-knees or hip issues?
  • • What safe and effective options do we have for managing chronic joint and bone pain?

Questions for You

  • • Have I noticed any changes in how far I can walk or my energy levels during physical activities?
  • • Am I experiencing snoring, gasping, or restlessness during sleep that could indicate airway issues?
  • • Am I prepared for the weekly time commitment of ERT infusions, and have I discussed this with my support system?
  • • How is my current pain level affecting my daily quality of life, and do I need to ask for a referral to a pain specialist?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    A pictorial review of the radiographic skeletal findings in Morquio syndrome (mucopolysaccharidosis type IV).

    Padash S, Obaid H, Henderson RDE, et al.

    Pediatric radiology 2023; (53(5)):971-983 doi:10.1007/s00247-022-05585-3.

    PMID: 36627376
  2. 2

    Clinical outcomes in elderly patients with Morquio a syndrome receiving enzyme replacement therapy - experience in a Colombian center.

    Erazo-Narváez AF, Muñoz-Vidal JM, Rodríguez-Vélez GH, Acosta-Aragón MA

    Molecular genetics and metabolism reports 2020; (25()):100679 doi:10.1016/j.ymgmr.2020.100679.

    PMID: 33304816
  3. 3

    Efficacy of Intravenous Elosulfase Alfa for Mucopolysaccharidosis Type IVA: A Systematic Review and Meta-Analysis.

    Lee CL, Chuang CK, Syu YM, et al.

    Journal of personalized medicine 2022; (12(8)) doi:10.3390/jpm12081338.

    PMID: 36013287
  4. 4

    Role of elosulfase alfa in mucopolysaccharidosis IVA.

    Regier DS, Tanpaiboon P

    The application of clinical genetics 2016; (9()):67-74 doi:10.2147/TACG.S69080.

    PMID: 27366102
  5. 5

    Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England.

    Cleary M, Davison J, Gould R, et al.

    Orphanet journal of rare diseases 2021; (16(1)):38 doi:10.1186/s13023-021-01675-x.

    PMID: 33478511
  6. 6

    Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome.

    Hendriksz CJ, Parini R, AlSayed MD, et al.

    Molecular genetics and metabolism 2016; (119(1-2)):131-43.

    PMID: 27380995
  7. 7

    Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa.

    Hughes D, Giugliani R, Guffon N, et al.

    Orphanet journal of rare diseases 2017; (12(1)):98 doi:10.1186/s13023-017-0634-0.

    PMID: 28535791
  8. 8

    Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome.

    Hendriksz CJ, Berger KI, Parini R, et al.

    Journal of inherited metabolic disease 2016; (39(6)):839-847 doi:10.1007/s10545-016-9973-6.

    PMID: 27553181
  9. 9

    Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management.

    Sawamoto K, Álvarez González JV, Piechnik M, et al.

    International journal of molecular sciences 2020; (21(4)) doi:10.3390/ijms21041517.

    PMID: 32102177
  10. 10

    Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations.

    Tomatsu S, Sawamoto K, Shimada T, et al.

    Expert opinion on orphan drugs 2015; (3(11)):1279-1290 doi:10.1517/21678707.2015.1086640.

    PMID: 26973801
  11. 11

    Clinical characteristics and effects of enzyme replacement therapy with elosulfase alfa in Korean patients with mucopolysaccharidosis type IVA.

    Lee SH, Kim HY, Cho TJ, et al.

    Molecular genetics and metabolism reports 2022; (31()):100869 doi:10.1016/j.ymgmr.2022.100869.

    PMID: 35782601
  12. 12

    Anesthetic and Airway Management in a Pediatric Patient with Morquio Syndrome: A Case Report.

    Garcia YKG, Reyes CRB

    Acta medica Philippina 2024; (58(9)):35-38 doi:10.47895/amp.v58i9.8284.

    PMID: 38836079
  13. 13

    Atlantoaxial instability treated with free-hand C1-C2 fusion in a child with Morquio syndrome.

    Moon E, Lee S, Chong S, Park JH

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2020; (36(8)):1785-1789 doi:10.1007/s00381-020-04561-2.

    PMID: 32172394
  14. 14

    CORONAL PLANE GROWTH MODULATION FOR GENU VALGUM IN SKELETAL DYSPLASIA.

    Sağlam Y, Demirel M, Yildirim AM, et al.

    Acta ortopedica brasileira 2022; (30(6)):e249113 doi:10.1590/1413-785220223006e249113.

    PMID: 36561480
  15. 15

    Corrections of diverse forms of lower limb deformities in patients with mucopolysaccharidosis type IVA (Morquio syndrome).

    Al Kaissi A, Kenis V, Melchenko E, et al.

    African journal of paediatric surgery : AJPS 2016; (13(2)):88-94 doi:10.4103/0189-6725.182563.

    PMID: 27251659
  16. 16

    Total Hip Arthroplasty in a Patient with Mucopolysaccharidosis Type IVB.

    van den Eeden YNT, Unter Ecker N, Kleinertz H, et al.

    Case reports in orthopedics 2021; (2021()):5584408 doi:10.1155/2021/5584408.

    PMID: 34012686
  17. 17

    Otorhinolaryngological manifestations in 61 patients with mucopolysaccharidosis.

    Murgasova L, Jurovcik M, Jesina P, et al.

    International journal of pediatric otorhinolaryngology 2020; (135()):110137 doi:10.1016/j.ijporl.2020.110137.

    PMID: 32502916
  18. 18

    Evaluation of sleep-disordered breathing and its relationship with respiratory parameters in children with mucopolysaccharidosis Type IVA and VI.

    Ademhan Tural D, Emiralioglu N, Dogru D, et al.

    American journal of medical genetics. Part A 2021; (185(8)):2306-2314 doi:10.1002/ajmg.a.62229.

    PMID: 33960649
  19. 19

    How did intraoperative neuromonitorization prevent tetraplegia?

    Sahin MC, Ipek EM, Zinnuroglu M, Borcek AO

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2023; (39(5)):1323-1328 doi:10.1007/s00381-022-05748-5.

    PMID: 36400977
  20. 20

    Hearing loss in patients with Morquio A syndrome: A scoping review.

    Diaz-Ordoñez L, Duque-Cordoba PA, Silva-Cuero K, et al.

    Medicine 2025; (104(2)):e41128 doi:10.1097/MD.0000000000041128.

    PMID: 39792720
  21. 21

    Non-invasive pulmonary function test on Morquio patients.

    Doherty C, Kubaski F, Tomatsu S, Shaffer TH

    Journal of rare diseases research & treatment 2017; (2(2)):55-62.

    PMID: 30294725
  22. 22

    Intraoperative Neuromonitoring Assists in Detecting Positioning-Associated Ischemia in Non-Spine Surgery in Morquio Syndrome: A Case Report.

    Bharadwaj AD, Markowitz SD, Zertan C, Zimmerman AM

    A&A practice 2025; (19(11)):e02072 doi:10.1213/XAA.0000000000002072.

    PMID: 41212691

This page explains treatment options and standard of care for Morquio Syndrome (MPS IV) for educational purposes only. Always consult your multidisciplinary healthcare team before making any changes to your care plan.

Stay up to date

Get notified when new research about Mucopolysaccharidosis type 4 is published.

No spam. Unsubscribe anytime.